Clinical Trial Update: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) [Phase 1, Phase 2]

View source ↗

Summary

A safety and preliminary efficacy study of CC-99282, alone and in combination with anti-lymphoma agents, for relapsed or refractory Non-Hodgkin Lymphoma, curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CC-99282

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING